



Rational Design and Standardized Evaluation of Novel Genetic Vaccines

Paris June 29, 2009
Collège de France
Amphithéâtre Halbwachs



There is no registration fee for the meeting, but you are requested to register with
Adeline Lassaux adeline.lassaux@upmc.fr



8.30 Welcome address: Jean-Charles Pomerol (Président Université Pierre et Marie Curie)

Marc Lipinski (Vice-Président du conseil régional Ile De France)

8.45-9 CompuVac's endeavor

David Klatzmann (CompuVac's coordinator)

9-10.40 Immunity and infection

- Michael J. Brennan, Ph.D, Senior Advisor, Global Affairs, Aeras Global TB Vaccine Foundation: **Immune response to Tuberculosis, implication for vaccine development.**

- Brigitte Autran, Prof, MD, PhD, Director Biomedical Investigation Center, Hospital Pitié-Salpêtrière, Paris: **Immune response to HIV, implication for vaccine development.**

- Christian Bréchet, MD, PhD, Vice President for medical and scientific affairs, Mérieux Alliance France: **Immune response to HCV/HBV, implication for vaccine development.**

10.40-11 Coffee break

11-11.30 Systems Immunology in vaccine development

- Thomas Kepler, PhD, Head Laboratory of Computational Immunology, Human Vaccine Institute, Duke University, School of Medicine: **Computational systems immunology for adjuvant development**

11.30-12.30 Challenges in vaccine development

- Jean-François Delfraissy, MD, PhD, Prof, Director, National Agency for Research into AIDS and Viral Hepatitis (ANRS): **The national perspective**

- Ruxandra Draghia-Akli, MD, PhD, Head of the Health Directorate, European Commission: **The EU perspective.**

- Peter Piot, MD, PhD, Director Institute for Global Health, Imperial College London: **The international perspective.**

12.30-13.30 Lunch (on site buffet)



13.30-15 Vaccine development issues

- Philippe Kourilsky, Prof, PhD, Chairman & Principal Investigator at the Singapore Immunology Network: **Social issues related to vaccine development.**

- Anna-Lise Williamson, Prof, PhD, Principal Investigator HIV Vaccine Development Group and HPV Research Group: **Development of HIV-1 Vaccines for Africa.**

- Murray Gardner Prof, MD, Center for Comparative Medicine, UC Davis USA: **Animal Models for Vaccine Research.**

15-15.30 Coffee break

15.30-17 Vaccine development: difficult case studies

- Norman Letvin, Prof, MD, Director of the Non-Human Primate Research Program at the NIH Vaccine Research Center: **The case of HIV.**

- Albert Osterhaus, Prof, DVM, PhD, Head of the Department of Virology, Erasmus MC Rotterdam: **The case of Flu.**

- Charlotte Dalba, M.D., Ph.D., CEO Epixis: **The case of HCV**

17-17.45 CompuVac's achievements

David Klatzmann (CompuVac's Coordinator)

17.45-18.30 GeVaDSs' presentation & demonstration

- Jacek Blazewicz, Prof, PhD Deputy Director of the Institute of Computing Science, PUT

- Adrien Six, PhD, Assistant-professor in Immunology, UPMC

18.30-18.45 Official opening of the online access to the CompuVac's database and toolbox with representatives from EC/CNRS/UPMC/ and CompuVac's partners

18.45-19.45 Press conference

18.45-20 Cocktail

Centre National de la Recherche Scientifique

Université Pierre et Marie Curie

ASLA biotech

Poznan University of Technology

Institute of Immunology

Institut National de la Santé et de la Recherche Médicale

CYTOS biotech

Karolinska Institute

EPIXIS biotech

Université Claude Bernard Lyon

University of Ulm

Hellenic Pasteur Institute

Latvian BioMedical Research & Study Center

Institute of Bio Technology

University of Geneva

University of Cape Town

Pasteur Institute

